The Board of Metropolis Healthcare at its meeting held on 09 December 2024 has approved the acquisition of the 100% stake in Core Diagnostics, India, (Core Diagnostics) from its existing shareholder, Core Diagnostics (Mauritius) for a total purchase consideration of Rs 246.83 crore to be discharged partly by cash and partly by way of preferential issue and allotment of equity shares of the Company (by way of share swap) subject to approval of the shareholders of the Company. Pursuant to the completion of acquisition, Core Diagnostics will become a wholly owned subsidiary of the Company. Powered by Capital Market - Live News

Metropolis Healthcare will hold a meeting of the Board of Directors of the Company on 9 December 2024Powered by Capital Market - Live News

Net profit of Metropolis Healthcare rose 31.23% to Rs 46.52 crore in the quarter ended September 2024 as against Rs 35.45 crore during the previous quarter ended September 2023. Sales rose 13.38% to Rs 349.79 crore in the quarter ended September 2024 as against Rs 308.50 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales349.79308.50 13 OPM %25.7024.25 - PBDT88.2170.35 25 PBT61.4048.11 28 NP46.5235.45 31 Powered by Capital Market - Live News

Metropolis Healthcare will hold a meeting of the Board of Directors of the Company on 8 November 2024Powered by Capital Market - Live News

Metropolis Healthcare will hold a meeting of the Board of Directors of the Company on 8 November 2024Powered by Capital Market - Live News